Su L, Li Q, Zhu L, et al. - Researchers conducted the study for examining the changes in macular vessel density (mVD) and its connection to macular ganglion cell–inner plexiform layer (mGCIPL) thickness in patients receiving ethambutol (EMB) therapy for tuberculosis without recognisable clinical symptoms or signs of EMB-induced optic neuropathy (EON). In total, 23 eyes of 13 patients using EMB therapy for 6 months without EON (preclinical EON) as the EMB group, 40 eyes of 23 healthy people as the normal control group and 18 eyes of 10 patients with tuberculosis before receiving EMB therapy as the blank control group have been retrospectively analyzed. With no changes in mGCIPL and mean pRNFL thickness, central circle mVD (cCVD) decreased in preclinical EON patients. cCVD was positively correlated with the minimum and inferonasal mGCIPL thicknesses. For monitoring early-stage EMB toxicity, cCVD could be an early indicator.